JCS/T2D JCS/T2D
JCS/T2D JCS/T2D
  • Home
  • About
  • Disclaimer
  • Privacy

Details
By J. Smith
J. Smith
Disclaimer
06 May 2023
Last Updated: 14 January 2026
Hits: 824
  • Medical Disclaimer
  • Health Information
  • Non-Medical Advice
  • Educational Content
  • Patient Resources

Disclaimer

General Terms

This web site is provided for educational and informational purposes only and is not medical advice or a professional service. The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Always seek the advice of your doctor or other qualified health provider regarding any medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website. If you think you may have a medical emergency, call 9-1-1 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. JCS/T2D and any contributors, make no representations, express or implied, with respect to the information provided herein or to its use.

Conflicts of Interest

We have no commercial or financial relationships that could be construed as actual or potential conflicts of interest.

Articles

  • Professor Juleen R. Zierath: Three Decades of Showing How Exercise Changes Metabolism
  • A More Human View of Glucose: How Hourly Visualizations Reduce Anxiety and Reveal Real Patterns
  • Wegovy Will Not Go OTC: What the Sources Actually Say
  • Bridging Data and Healthcare in the Nordics
  • How Well Do My CGM and BGM Readings Match?
  • Epigenetic Clues to Heart Risk in Type 2 Diabetes
  • Could a Gut Bacterium Help Transform Diabetes and Obesity Care?
  • Why mRNAs Are a Good Option for Vaccines
  • Why I Took Medical Courses to Strengthen My Data Skills
  • New Research Reveals the Hidden Complexity of Insulin Resistance
  • What the 2025 Diabetes Care Updates Mean for You
  • How an Hour-by-Hour View Transforms Time in Range Insights
  • Successfully Completed: Diabetes – A Global Challenge
  • Join the 5K@ADA Virtual Challenge to Promote Diabetes Awareness and Healthy Living
  • How Tirzepatide is Revolutionizing Type 2 Diabetes Prevention in Overweight and Obese Adults
  • Eli Lilly and Novo Nordisk Invest in Increased Manufacturing Capacity for GLP-1 Drugs
  • FDA Issues Alert on Compounded Semaglutide Dosing Errors
  • Join the 5K@EASD Virtual Challenge to Promote Diabetes Awareness and Healthy Living
  • Regulatory Hurdles for Awiqli: Approval in Canada and EU, Concerns in the US
  • Tirzepatide’s Efficacy in Treating Obstructive Sleep Apnea

News

April 2026

  • New ACHIEVE-4 Data May Help Address FDA Safety Questions on Lilly’s Foundayo
  • Novo Nordisk Expands AI Strategy Through New OpenAI Partnership
  • Lilly’s Foundayo Approval Brings a More Flexible GLP-1 Pill to Weight Loss Care

March 2026

  • Novo Nordisk Reports Promising Phase 2 Data for UBT251 in Type 2 Diabetes
  • Novo Nordisk Expands DTC Push With New Wegovy Subscription Program
  • FDA Approves Awiqli as First Once-Weekly Basal Insulin for Type 2 Diabetes
  • Retatrutide’s First Phase 3 Diabetes Results Draw Attention for More Than Strong Numbers
  • FDA Approves Wegovy HD, Adding a Higher-Dose Semaglutide Option for Obesity
  • Zealand Pharma Reports Phase 2 Results for Petrelintide

February 2026

  • REDEFINE-4 Results: What They Mean for Patients
  • Novo Nordisk Renames Oral Semaglutide as Ozempic Pill Ahead of U.S. Launch

Top Subjects

  • Type 2 Diabetes
  • Novo Nordisk
  • Obesity Treatment
  • GLP-1
  • Wegovy
  • Semaglutide
  • Eli Lilly
  • Tirzepatide
  • Ozempic
  • Zepbound
  • FDA Approval
  • Diabetes
  • Obesity
  • Diabetes Management
  • Continuous Glucose Monitoring
  • Orforglipron
  • Mounjaro
  • Clinical Trials
  • Metabolic Health
  • Obesity Care
  • Dexcom
  • CGM
  • FDA
  • Weight Loss
  • Oral Semaglutide
  • Rybelsus
  • Diabetes Treatment
  • Once-Weekly Insulin
  • Dexcom G7
  • Liraglutide

Contact Us

Search

5K@ADA

5K@EASD

World Obesity Day

Rochen Web Hosting

Bluesky Social

  • You are here:  
  • Home
  • Disclaimer
  • Disclaimer
 
Copyright © 2026 JCS/T2D - A Diabetes Journey. All Rights Reserved.
Joomla! is Free Software released under the GNU General Public License.